The data presented in Appendix I of Kalbfleisch and Prentice (1980) are coded in the following DATA step. The response variable, SurvTime
, is the survival time in days of a lung cancer patient. Negative values of SurvTime
are censored values. The covariates are Cell
(type of cancer cell), Therapy
(type of therapy: standard or test), Prior
(prior therapy: 0=no, 10=yes), Age
(age in years), DiagTime
(time in months from diagnosis to entry into the trial), and Kps
(performance status). A censoring indicator variable Censor
is created from the data, with the value 1 indicating a censored time and the value 0 indicating an event time. Since there
are only two types of therapy, an indicator variable, Treatment
, is constructed for therapy type, with value 0 for standard therapy and value 1 for test therapy.
data VALung; drop check m; retain Therapy Cell; infile cards column=column; length Check $ 1; label SurvTime='Failure or Censoring Time' Kps='Karnofsky Index' DiagTime='Months till Randomization' Age='Age in Years' Prior='Prior Treatment?' Cell='Cell Type' Therapy='Type of Treatment' Treatment='Treatment Indicator'; M=Column; input Check $ @@; if M>Column then M=1; if Check='s'|Check='t' then input @M Therapy $ Cell $ ; else input @M SurvTime Kps DiagTime Age Prior @@; if SurvTime > .; censor=(SurvTime<0); SurvTime=abs(SurvTime); Treatment=(Therapy='test'); datalines; standard squamous 72 60 7 69 0 411 70 5 64 10 228 60 3 38 0 126 60 9 63 10 118 70 11 65 10 10 20 5 49 0 82 40 10 69 10 110 80 29 68 0 314 50 18 43 0 -100 70 6 70 0 42 60 4 81 0 8 40 58 63 10 144 30 4 63 0 -25 80 9 52 10 11 70 11 48 10 standard small 30 60 3 61 0 384 60 9 42 0 4 40 2 35 0 54 80 4 63 10 13 60 4 56 0 -123 40 3 55 0 -97 60 5 67 0 153 60 14 63 10 59 30 2 65 0 117 80 3 46 0 16 30 4 53 10 151 50 12 69 0 22 60 4 68 0 56 80 12 43 10 21 40 2 55 10 18 20 15 42 0 139 80 2 64 0 20 30 5 65 0 31 75 3 65 0 52 70 2 55 0 287 60 25 66 10 18 30 4 60 0 51 60 1 67 0 122 80 28 53 0 27 60 8 62 0 54 70 1 67 0 7 50 7 72 0 63 50 11 48 0 392 40 4 68 0 10 40 23 67 10 standard adeno 8 20 19 61 10 92 70 10 60 0 35 40 6 62 0 117 80 2 38 0 132 80 5 50 0 12 50 4 63 10 162 80 5 64 0 3 30 3 43 0 95 80 4 34 0 standard large 177 50 16 66 10 162 80 5 62 0 216 50 15 52 0 553 70 2 47 0 278 60 12 63 0 12 40 12 68 10 260 80 5 45 0 200 80 12 41 10 156 70 2 66 0 -182 90 2 62 0 143 90 8 60 0 105 80 11 66 0 103 80 5 38 0 250 70 8 53 10 100 60 13 37 10 test squamous 999 90 12 54 10 112 80 6 60 0 -87 80 3 48 0 -231 50 8 52 10 242 50 1 70 0 991 70 7 50 10 111 70 3 62 0 1 20 21 65 10 587 60 3 58 0 389 90 2 62 0 33 30 6 64 0 25 20 36 63 0 357 70 13 58 0 467 90 2 64 0 201 80 28 52 10 1 50 7 35 0 30 70 11 63 0 44 60 13 70 10 283 90 2 51 0 15 50 13 40 10 test small 25 30 2 69 0 -103 70 22 36 10 21 20 4 71 0 13 30 2 62 0 87 60 2 60 0 2 40 36 44 10 20 30 9 54 10 7 20 11 66 0 24 60 8 49 0 99 70 3 72 0 8 80 2 68 0 99 85 4 62 0 61 70 2 71 0 25 70 2 70 0 95 70 1 61 0 80 50 17 71 0 51 30 87 59 10 29 40 8 67 0 test adeno 24 40 2 60 0 18 40 5 69 10 -83 99 3 57 0 31 80 3 39 0 51 60 5 62 0 90 60 22 50 10 52 60 3 43 0 73 60 3 70 0 8 50 5 66 0 36 70 8 61 0 48 10 4 81 0 7 40 4 58 0 140 70 3 63 0 186 90 3 60 0 84 80 4 62 10 19 50 10 42 0 45 40 3 69 0 80 40 4 63 0 test large 52 60 4 45 0 164 70 15 68 10 19 30 4 39 10 53 60 12 66 0 15 30 5 63 0 43 60 11 49 10 340 80 10 64 10 133 75 1 65 0 111 60 5 64 0 231 70 18 67 10 378 80 4 65 0 49 30 3 37 0 ;
In the following statements, PROC LIFETEST is invoked to compute the product-limit estimate of the survivor function for each
type of cancer cell and to analyze the effects of the variables Age
, Prior
, DiagTime
, Kps
, and Treatment
on the survival of the patients. These prognostic factors are specified in the TEST statement, and the variable Cell
is specified in the STRATA statement. ODS Graphics must be enabled before producing graphs. Graphical displays of the product-limit
estimates (S), the negative log estimates (LS), and the log of negative log estimates (LLS) are requested through the PLOTS=
option in the PROC LIFETEST statement. Because of a few large survival times, a MAXTIME of 600 is used to set the scale of
the time axis; that is, the time scale extends from 0 to a maximum of 600 days in the plots. The variable Therapy
is specified in the ID statement to identify the type of therapy for each observation in the product-limit estimates. The
OUTTEST option specifies the creation of an output data set named Test
to contain the rank test matrices for the covariates.
ods graphics on; proc lifetest data=VALung plots=(s,ls,lls) outtest=Test maxtime=600; time SurvTime*Censor(1); id Therapy; strata Cell; test Age Prior DiagTime Kps Treatment; run; ods graphics off;
Output 58.1.1 through Output 58.1.4 display the product-limit estimates of the survivor functions for the four cell types. Summary statistics of the survival times are also shown. The median survival times are 51 days, 156 days, 51 days, and 118 days for patients with adeno cells, large cells, small cells, and squamous cells, respectively.
Output 58.1.1: Estimation Results for Adeno Cells
Product-Limit Survival Estimates | |||||||
---|---|---|---|---|---|---|---|
SurvTime | Survival | Failure | Survival Standard Error |
Number Failed |
Number Left |
Therapy | |
0.000 | 1.0000 | 0 | 0 | 0 | 27 | ||
3.000 | 0.9630 | 0.0370 | 0.0363 | 1 | 26 | standard | |
7.000 | 0.9259 | 0.0741 | 0.0504 | 2 | 25 | test | |
8.000 | . | . | . | 3 | 24 | standard | |
8.000 | 0.8519 | 0.1481 | 0.0684 | 4 | 23 | test | |
12.000 | 0.8148 | 0.1852 | 0.0748 | 5 | 22 | standard | |
18.000 | 0.7778 | 0.2222 | 0.0800 | 6 | 21 | test | |
19.000 | 0.7407 | 0.2593 | 0.0843 | 7 | 20 | test | |
24.000 | 0.7037 | 0.2963 | 0.0879 | 8 | 19 | test | |
31.000 | 0.6667 | 0.3333 | 0.0907 | 9 | 18 | test | |
35.000 | 0.6296 | 0.3704 | 0.0929 | 10 | 17 | standard | |
36.000 | 0.5926 | 0.4074 | 0.0946 | 11 | 16 | test | |
45.000 | 0.5556 | 0.4444 | 0.0956 | 12 | 15 | test | |
48.000 | 0.5185 | 0.4815 | 0.0962 | 13 | 14 | test | |
51.000 | 0.4815 | 0.5185 | 0.0962 | 14 | 13 | test | |
52.000 | 0.4444 | 0.5556 | 0.0956 | 15 | 12 | test | |
73.000 | 0.4074 | 0.5926 | 0.0946 | 16 | 11 | test | |
80.000 | 0.3704 | 0.6296 | 0.0929 | 17 | 10 | test | |
83.000 | * | . | . | . | 17 | 9 | test |
84.000 | 0.3292 | 0.6708 | 0.0913 | 18 | 8 | test | |
90.000 | 0.2881 | 0.7119 | 0.0887 | 19 | 7 | test | |
92.000 | 0.2469 | 0.7531 | 0.0850 | 20 | 6 | standard | |
95.000 | 0.2058 | 0.7942 | 0.0802 | 21 | 5 | standard | |
117.000 | 0.1646 | 0.8354 | 0.0740 | 22 | 4 | standard | |
132.000 | 0.1235 | 0.8765 | 0.0659 | 23 | 3 | standard | |
140.000 | 0.0823 | 0.9177 | 0.0553 | 24 | 2 | test | |
162.000 | 0.0412 | 0.9588 | 0.0401 | 25 | 1 | standard | |
186.000 | 0 | 1.0000 | . | 26 | 0 | test |
Note: | The marked survival times are censored observations. |
Output 58.1.2: Estimation Results for Large Cells
Product-Limit Survival Estimates | |||||||
---|---|---|---|---|---|---|---|
SurvTime | Survival | Failure | Survival Standard Error |
Number Failed |
Number Left |
Therapy | |
0.000 | 1.0000 | 0 | 0 | 0 | 27 | ||
12.000 | 0.9630 | 0.0370 | 0.0363 | 1 | 26 | standard | |
15.000 | 0.9259 | 0.0741 | 0.0504 | 2 | 25 | test | |
19.000 | 0.8889 | 0.1111 | 0.0605 | 3 | 24 | test | |
43.000 | 0.8519 | 0.1481 | 0.0684 | 4 | 23 | test | |
49.000 | 0.8148 | 0.1852 | 0.0748 | 5 | 22 | test | |
52.000 | 0.7778 | 0.2222 | 0.0800 | 6 | 21 | test | |
53.000 | 0.7407 | 0.2593 | 0.0843 | 7 | 20 | test | |
100.000 | 0.7037 | 0.2963 | 0.0879 | 8 | 19 | standard | |
103.000 | 0.6667 | 0.3333 | 0.0907 | 9 | 18 | standard | |
105.000 | 0.6296 | 0.3704 | 0.0929 | 10 | 17 | standard | |
111.000 | 0.5926 | 0.4074 | 0.0946 | 11 | 16 | test | |
133.000 | 0.5556 | 0.4444 | 0.0956 | 12 | 15 | test | |
143.000 | 0.5185 | 0.4815 | 0.0962 | 13 | 14 | standard | |
156.000 | 0.4815 | 0.5185 | 0.0962 | 14 | 13 | standard | |
162.000 | 0.4444 | 0.5556 | 0.0956 | 15 | 12 | standard | |
164.000 | 0.4074 | 0.5926 | 0.0946 | 16 | 11 | test | |
177.000 | 0.3704 | 0.6296 | 0.0929 | 17 | 10 | standard | |
182.000 | * | . | . | . | 17 | 9 | standard |
200.000 | 0.3292 | 0.6708 | 0.0913 | 18 | 8 | standard | |
216.000 | 0.2881 | 0.7119 | 0.0887 | 19 | 7 | standard | |
231.000 | 0.2469 | 0.7531 | 0.0850 | 20 | 6 | test | |
250.000 | 0.2058 | 0.7942 | 0.0802 | 21 | 5 | standard | |
260.000 | 0.1646 | 0.8354 | 0.0740 | 22 | 4 | standard | |
278.000 | 0.1235 | 0.8765 | 0.0659 | 23 | 3 | standard | |
340.000 | 0.0823 | 0.9177 | 0.0553 | 24 | 2 | test | |
378.000 | 0.0412 | 0.9588 | 0.0401 | 25 | 1 | test | |
553.000 | 0 | 1.0000 | . | 26 | 0 | standard |
Note: | The marked survival times are censored observations. |
Output 58.1.3: Estimation Results for Small Cells
Product-Limit Survival Estimates | |||||||
---|---|---|---|---|---|---|---|
SurvTime | Survival | Failure | Survival Standard Error |
Number Failed |
Number Left |
Therapy | |
0.000 | 1.0000 | 0 | 0 | 0 | 48 | ||
2.000 | 0.9792 | 0.0208 | 0.0206 | 1 | 47 | test | |
4.000 | 0.9583 | 0.0417 | 0.0288 | 2 | 46 | standard | |
7.000 | . | . | . | 3 | 45 | standard | |
7.000 | 0.9167 | 0.0833 | 0.0399 | 4 | 44 | test | |
8.000 | 0.8958 | 0.1042 | 0.0441 | 5 | 43 | test | |
10.000 | 0.8750 | 0.1250 | 0.0477 | 6 | 42 | standard | |
13.000 | . | . | . | 7 | 41 | standard | |
13.000 | 0.8333 | 0.1667 | 0.0538 | 8 | 40 | test | |
16.000 | 0.8125 | 0.1875 | 0.0563 | 9 | 39 | standard | |
18.000 | . | . | . | 10 | 38 | standard | |
18.000 | 0.7708 | 0.2292 | 0.0607 | 11 | 37 | standard | |
20.000 | . | . | . | 12 | 36 | standard | |
20.000 | 0.7292 | 0.2708 | 0.0641 | 13 | 35 | test | |
21.000 | . | . | . | 14 | 34 | standard | |
21.000 | 0.6875 | 0.3125 | 0.0669 | 15 | 33 | test | |
22.000 | 0.6667 | 0.3333 | 0.0680 | 16 | 32 | standard | |
24.000 | 0.6458 | 0.3542 | 0.0690 | 17 | 31 | test | |
25.000 | . | . | . | 18 | 30 | test | |
25.000 | 0.6042 | 0.3958 | 0.0706 | 19 | 29 | test | |
27.000 | 0.5833 | 0.4167 | 0.0712 | 20 | 28 | standard | |
29.000 | 0.5625 | 0.4375 | 0.0716 | 21 | 27 | test | |
30.000 | 0.5417 | 0.4583 | 0.0719 | 22 | 26 | standard | |
31.000 | 0.5208 | 0.4792 | 0.0721 | 23 | 25 | standard | |
51.000 | . | . | . | 24 | 24 | standard | |
51.000 | 0.4792 | 0.5208 | 0.0721 | 25 | 23 | test | |
52.000 | 0.4583 | 0.5417 | 0.0719 | 26 | 22 | standard | |
54.000 | . | . | . | 27 | 21 | standard | |
54.000 | 0.4167 | 0.5833 | 0.0712 | 28 | 20 | standard | |
56.000 | 0.3958 | 0.6042 | 0.0706 | 29 | 19 | standard | |
59.000 | 0.3750 | 0.6250 | 0.0699 | 30 | 18 | standard | |
61.000 | 0.3542 | 0.6458 | 0.0690 | 31 | 17 | test | |
63.000 | 0.3333 | 0.6667 | 0.0680 | 32 | 16 | standard | |
80.000 | 0.3125 | 0.6875 | 0.0669 | 33 | 15 | test | |
87.000 | 0.2917 | 0.7083 | 0.0656 | 34 | 14 | test | |
95.000 | 0.2708 | 0.7292 | 0.0641 | 35 | 13 | test | |
97.000 | * | . | . | . | 35 | 12 | standard |
99.000 | . | . | . | 36 | 11 | test | |
99.000 | 0.2257 | 0.7743 | 0.0609 | 37 | 10 | test | |
103.000 | * | . | . | . | 37 | 9 | test |
117.000 | 0.2006 | 0.7994 | 0.0591 | 38 | 8 | standard | |
122.000 | 0.1755 | 0.8245 | 0.0567 | 39 | 7 | standard | |
123.000 | * | . | . | . | 39 | 6 | standard |
139.000 | 0.1463 | 0.8537 | 0.0543 | 40 | 5 | standard | |
151.000 | 0.1170 | 0.8830 | 0.0507 | 41 | 4 | standard | |
153.000 | 0.0878 | 0.9122 | 0.0457 | 42 | 3 | standard | |
287.000 | 0.0585 | 0.9415 | 0.0387 | 43 | 2 | standard | |
384.000 | 0.0293 | 0.9707 | 0.0283 | 44 | 1 | standard | |
392.000 | 0 | 1.0000 | . | 45 | 0 | standard |
Note: | The marked survival times are censored observations. |
Output 58.1.4: Estimation Results for Squamous Cells
Product-Limit Survival Estimates | |||||||
---|---|---|---|---|---|---|---|
SurvTime | Survival | Failure | Survival Standard Error |
Number Failed |
Number Left |
Therapy | |
0.000 | 1.0000 | 0 | 0 | 0 | 35 | ||
1.000 | . | . | . | 1 | 34 | test | |
1.000 | 0.9429 | 0.0571 | 0.0392 | 2 | 33 | test | |
8.000 | 0.9143 | 0.0857 | 0.0473 | 3 | 32 | standard | |
10.000 | 0.8857 | 0.1143 | 0.0538 | 4 | 31 | standard | |
11.000 | 0.8571 | 0.1429 | 0.0591 | 5 | 30 | standard | |
15.000 | 0.8286 | 0.1714 | 0.0637 | 6 | 29 | test | |
25.000 | 0.8000 | 0.2000 | 0.0676 | 7 | 28 | test | |
25.000 | * | . | . | . | 7 | 27 | standard |
30.000 | 0.7704 | 0.2296 | 0.0713 | 8 | 26 | test | |
33.000 | 0.7407 | 0.2593 | 0.0745 | 9 | 25 | test | |
42.000 | 0.7111 | 0.2889 | 0.0772 | 10 | 24 | standard | |
44.000 | 0.6815 | 0.3185 | 0.0794 | 11 | 23 | test | |
72.000 | 0.6519 | 0.3481 | 0.0813 | 12 | 22 | standard | |
82.000 | 0.6222 | 0.3778 | 0.0828 | 13 | 21 | standard | |
87.000 | * | . | . | . | 13 | 20 | test |
100.000 | * | . | . | . | 13 | 19 | standard |
110.000 | 0.5895 | 0.4105 | 0.0847 | 14 | 18 | standard | |
111.000 | 0.5567 | 0.4433 | 0.0861 | 15 | 17 | test | |
112.000 | 0.5240 | 0.4760 | 0.0870 | 16 | 16 | test | |
118.000 | 0.4912 | 0.5088 | 0.0875 | 17 | 15 | standard | |
126.000 | 0.4585 | 0.5415 | 0.0876 | 18 | 14 | standard | |
144.000 | 0.4257 | 0.5743 | 0.0873 | 19 | 13 | standard | |
201.000 | 0.3930 | 0.6070 | 0.0865 | 20 | 12 | test | |
228.000 | 0.3602 | 0.6398 | 0.0852 | 21 | 11 | standard | |
231.000 | * | . | . | . | 21 | 10 | test |
242.000 | 0.3242 | 0.6758 | 0.0840 | 22 | 9 | test | |
283.000 | 0.2882 | 0.7118 | 0.0820 | 23 | 8 | test | |
314.000 | 0.2522 | 0.7478 | 0.0793 | 24 | 7 | standard | |
357.000 | 0.2161 | 0.7839 | 0.0757 | 25 | 6 | test | |
389.000 | 0.1801 | 0.8199 | 0.0711 | 26 | 5 | test | |
411.000 | 0.1441 | 0.8559 | 0.0654 | 27 | 4 | standard | |
467.000 | 0.1081 | 0.8919 | 0.0581 | 28 | 3 | test | |
587.000 | 0.0720 | 0.9280 | 0.0487 | 29 | 2 | test | |
991.000 | 0.0360 | 0.9640 | 0.0352 | 30 | 1 | test | |
999.000 | 0 | 1.0000 | . | 31 | 0 | test |
Note: | The marked survival times are censored observations. |
The distribution of event and censored observations among the four cell types is summarized in Output 58.1.5.
The graph of the estimated survivor functions is shown in Output 58.1.6. The adeno cell curve and the small cell curve are much closer to each other than they are to the large cell curve or the squamous cell curve. The survival rates of the adeno cell patients and the small cell patients decrease rapidly to approximately 29% in 90 days. Shapes of the large cell curve and the squamous cell curve are quite different, although both decrease less rapidly than those of the adeno and small cells. The squamous cell curve decreases more rapidly initially than the large cell curve, but the role is reversed in the later period.
The graph of the negative log of the estimated survivor functions is displayed in Output 58.1.7. Output 58.1.8 displays the log of the negative log of the estimated survivor functions against the log of time.
Results of the homogeneity tests across cell types are given in Output 58.1.9. The log-rank and Wilcoxon statistics and their corresponding covariance matrices are displayed. Also given is a table that consists of the approximate chi-square statistics, degrees of freedom, and p-values for the log-rank, Wilcoxon, and likelihood ratio tests. All three tests indicate strong evidence of a significant difference among the survival curves for the four types of cancer cells (p < 0.0001).
Results of the log-rank test of the prognostic variables are shown in Output 58.1.10. The univariate test results correspond to testing each prognostic factor marginally. The joint covariance matrix of these univariate test statistics is also displayed. In computing the overall chi-square statistic, the partial chi-square statistics following a forward stepwise entry approach are tabulated.
Consider the log-rank test in Output 58.1.10. Since the univariate test for Kps
has the largest chi-square (43.4747) among all the covariates, Kps
is entered first. At this stage, the partial chi-square and the chi-square increment for Kps
are the same as the univariate chi-square. Among all the covariates not in the model (Age
, Prior
, DiagTime
, Treatment
), Treatment
has the largest approximate chi-square increment (1.7261) and is entered next. The approximate chi-square for the model that
contains Kps
and Treatment
is 43.4747+1.7261=45.2008 with 2 degrees of freedom. The third covariate entered is Age
. The fourth is Prior
, and the fifth is DiagTime
. The overall chi-square statistic in the last line of the output is the partial chi-square for including all the covariates.
It has a value of 46.4200 with 5 degrees of freedom, which is highly significant (p < 0.0001).
Output 58.1.10: Log-Rank Test of the Prognostic Factors
Univariate Chi-Squares for the Log-Rank Test | |||||
---|---|---|---|---|---|
Variable | Test Statistic |
Standard Error |
Chi-Square | Pr > Chi-Square |
Label |
Age | -40.7383 | 105.7 | 0.1485 | 0.7000 | Age in Years |
Prior | -19.9435 | 46.9836 | 0.1802 | 0.6712 | Prior Treatment? |
DiagTime | -115.9 | 97.8708 | 1.4013 | 0.2365 | Months till Randomization |
Kps | 1123.1 | 170.3 | 43.4747 | <.0001 | Karnofsky Index |
Treatment | -4.2076 | 5.0407 | 0.6967 | 0.4039 | Treatment Indicator |
Forward Stepwise Sequence of Chi-Squares for the Log-Rank Test | ||||||
---|---|---|---|---|---|---|
Variable | DF | Chi-Square | Pr > Chi-Square |
Chi-Square Increment |
Pr > Increment |
Label |
Kps | 1 | 43.4747 | <.0001 | 43.4747 | <.0001 | Karnofsky Index |
Treatment | 2 | 45.2008 | <.0001 | 1.7261 | 0.1889 | Treatment Indicator |
Age | 3 | 46.3012 | <.0001 | 1.1004 | 0.2942 | Age in Years |
Prior | 4 | 46.4134 | <.0001 | 0.1122 | 0.7377 | Prior Treatment? |
DiagTime | 5 | 46.4200 | <.0001 | 0.00665 | 0.9350 | Months till Randomization |
You can establish this forward stepwise entry of prognostic factors by passing the matrix corresponding to the log-rank test to the RSQUARE method in the REG procedure, as follows. PROC REG finds the sets of variables that yield the largest chi-square statistics.
data RSq; set Test; if _type_='LOG RANK'; _type_='cov'; run; proc print data=RSq; run; proc reg data=RSq(type=COV); model SurvTime=Age Prior DiagTime Kps Treatment / selection=rsquare; title 'All Possible Subsets of Covariates for the log-rank Test'; run;
Output 58.1.11 displays the univariate statistics and their covariance matrix for the log-rank test.
Output 58.1.11: Log-Rank Statistics and Covariance Matrix
Obs | _TYPE_ | _NAME_ | SurvTime | Age | Prior | DiagTime | Kps | Treatment |
---|---|---|---|---|---|---|---|---|
1 | cov | SurvTime | 46.42 | -40.74 | -19.94 | -115.86 | 1123.14 | -4.208 |
2 | cov | Age | -40.74 | 11175.44 | -301.23 | -892.24 | -2948.45 | 119.297 |
3 | cov | Prior | -19.94 | -301.23 | 2207.46 | 2010.85 | 78.64 | 13.875 |
4 | cov | DiagTime | -115.86 | -892.24 | 2010.85 | 9578.69 | -2295.32 | 21.859 |
5 | cov | Kps | 1123.14 | -2948.45 | 78.64 | -2295.32 | 29015.62 | 61.945 |
6 | cov | Treatment | -4.21 | 119.30 | 13.87 | 21.86 | 61.95 | 25.409 |
Results of the best subset regression are shown in Output 58.1.12. The variable Kps
generates the largest univariate test statistic among all the covariates, the pair Kps
and Age
generate the largest test statistic among any other pairs of covariates, and so on. The entry order of covariates is identical
to that of PROC LIFETEST.
Output 58.1.12: Best Subset Regression from the REG Procedure
All Possible Subsets of Covariates for the log-rank Test |
Number in Model |
R-Square | Variables in Model |
---|---|---|
1 | 0.9366 | Kps |
1 | 0.0302 | DiagTime |
1 | 0.0150 | Treatment |
1 | 0.0039 | Prior |
1 | 0.0032 | Age |
2 | 0.9737 | Kps Treatment |
2 | 0.9472 | Age Kps |
2 | 0.9417 | Prior Kps |
2 | 0.9382 | DiagTime Kps |
2 | 0.0434 | DiagTime Treatment |
2 | 0.0353 | Age DiagTime |
2 | 0.0304 | Prior DiagTime |
2 | 0.0181 | Prior Treatment |
2 | 0.0159 | Age Treatment |
2 | 0.0075 | Age Prior |
3 | 0.9974 | Age Kps Treatment |
3 | 0.9774 | Prior Kps Treatment |
3 | 0.9747 | DiagTime Kps Treatment |
3 | 0.9515 | Age Prior Kps |
3 | 0.9481 | Age DiagTime Kps |
3 | 0.9418 | Prior DiagTime Kps |
3 | 0.0456 | Age DiagTime Treatment |
3 | 0.0438 | Prior DiagTime Treatment |
3 | 0.0355 | Age Prior DiagTime |
3 | 0.0192 | Age Prior Treatment |
4 | 0.9999 | Age Prior Kps Treatment |
4 | 0.9976 | Age DiagTime Kps Treatment |
4 | 0.9774 | Prior DiagTime Kps Treatment |
4 | 0.9515 | Age Prior DiagTime Kps |
4 | 0.0459 | Age Prior DiagTime Treatment |
5 | 1.0000 | Age Prior DiagTime Kps Treatment |